TEPMETKO (tepotinib)

Self Administration – Oral

Indications for Prior Authorization
  • Indicated for the treatment of adult patient with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
Coverage Criteria:

For diagnosis of metastatic non-small cell lung cancer (NSCLC):

  • Dose does not exceed 450 mg once daily, AND
  • Patient is 18 years of age or older, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Disease is metastatic, AND
  • Presence of mesenchymal-epithelial transition (MET) exon 14 skipping
Reauthorization Criteria:

For diagnosis of metastatic non-small cell lung cancer (NSCLC):

  • Dose does not exceed 450 mg once daily, AND
  • Patient does not show evidence of progressive disease while on therapy
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Tepmetko is the only approved once-daily oral MET inhibitor
  • Warnings and Precautions
    • Interstitial Lung Disease (ILD)/Pneumonitis – withhold Tepmetko in patients with suspected ILD/pneumonitis and permanently discontinue in patients diagnosed with ILD/pneumonitis of any severity
    • Hepatotoxicity – monitor liver function test.  Withhold, dose reduce, or permanently discontinue Tepmetko based on severity
    • Embryo-fetal toxicity – Tepmetko can cause fetal harm
  • Drug interactions
    • Dual strong CYP3A inhibitors and P-gp inhibitors: avoid concomitant use
    • Strong CYP3A inducers: avoid concomitant use
  • Certain P-gp substrates: avoid coadministration of Tepmetko with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities
Policy Updates:
  • 6/15/2021 – New policy approved by P&T
References:
  • ClinicalTrials.gov Web site. http://clinicaltrials.gov/. Accessed March 30, 2021.
  • Drilon A, Cark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26:47-51.
  • Ferrara R, Auger N, Auclin E, Besse B. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J Thorac Oncol. 2018;13(1):27-45. doi: 10.1016/j.jtho.2017.10.021.
  • Food and Drug Administration (FDA). Drug development and drug interactions: table of substrates, inhibitors and inducers. FDA Web site. March 10, 2020. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed March 30, 2021.
  • Food and Drug Administration (FDA). FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer [news release]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer. February 3, 2021. Accessed March 30, 2021.
  • Food and Drug Administration. Tepmetko multi-discipline review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214096Orig1s000MultidisciplineR.pdf. February 1, 2021. Accessed March 24, 2021.
  • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology – Non-small cell lung cancer. V4.2021. NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed March 23, 2021.
  • Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small cell lung cancer with MET exon 14 skipping alterations. N Engl J Med. 2020;383:931-943. doi: 10.1056/NEJMoa2004407.
  • Safi D, Abu Hejleh T, Furqan M. Narrative review: mesenchymal-epithelial transition inhibitors – meeting their target. Transl Lung Cancer Res. 2021;10(1):462-474. doi: 10.21037/tlcr-20-588.
  • Sequist LV, Neal JW. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. UpToDate Web site. Updated March 23, 2021. www.uptodate.com. Accessed March 24, 2021.
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi: 10.3322/caac.21654.
  • Tabrecta [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.
  • Tepmetko [package insert], Rockland, MA: EMD Serono, Inc.; February 2021.
  • Wolf J, Set T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-Amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944-957. doi: 10.1056/NEJMoa2002787.
  • Wu YL, Chen Y, Zhou J, et al for the INSIGHT Investigators. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicenter, randomized trial. Lancet Respir Med. 2020;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5.

 

Last review date: June 15, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone